Intelligent Bio Solutions to Highlight Proprietary Drug Testing Technology at 2025 NDASA Conference and Trade Show
Intelligent Bio Solutions (NASDAQ: INBS) announced its gold sponsorship at the 2025 National Drug and Alcohol Screening Association (NDASA) Conference, scheduled for April 1-4 in Jacksonville, Florida. Daniel Brown, Head of Clinical Affairs, will present the company's Intelligent Fingerprinting Drug Testing Solution on April 1.
The technology offers a portable, non-invasive drug screening method using fingerprint sweat, providing an alternative to traditional testing approaches. The company currently serves over 400 accounts across 19 countries in sectors including construction, transportation, mining, and manufacturing.
INBS is preparing to enter the U.S. drug screening market later this year, using the NDASA conference as a platform to engage with industry stakeholders and showcase their solution's relevance to the U.S. market.
Intelligent Bio Solutions (NASDAQ: INBS) ha annunciato il suo patrocinio d'oro alla Conferenza Nazionale dell'Associazione per lo Screening di Droga e Alcol (NDASA) del 2025, in programma dal 1 al 4 aprile a Jacksonville, Florida. Daniel Brown, Responsabile degli Affari Clinici, presenterà la soluzione di test per droghe Intelligent Fingerprinting il 1 aprile.
La tecnologia offre un metodo di screening per droga portatile e non invasivo che utilizza il sudore delle impronte digitali, fornendo un'alternativa agli approcci di test tradizionali. L'azienda attualmente serve oltre 400 clienti in 19 paesi in settori come costruzione, trasporti, estrazione mineraria e manifatturiero.
INBS si sta preparando a entrare nel mercato degli screening per droga negli Stati Uniti entro la fine di quest'anno, utilizzando la conferenza NDASA come piattaforma per interagire con i soggetti del settore e mostrare la rilevanza della loro soluzione per il mercato statunitense.
Intelligent Bio Solutions (NASDAQ: INBS) anunció su patrocinio dorado en la Conferencia Nacional de la Asociación de Screening de Drogas y Alcohol (NDASA) 2025, programada del 1 al 4 de abril en Jacksonville, Florida. Daniel Brown, Jefe de Asuntos Clínicos, presentará la Solución de Prueba de Drogas Intelligent Fingerprinting el 1 de abril.
La tecnología ofrece un método de detección de drogas portátil y no invasivo utilizando el sudor de las huellas dactilares, proporcionando una alternativa a los enfoques de prueba tradicionales. La empresa atiende actualmente a más de 400 cuentas en 19 países en sectores que incluyen construcción, transporte, minería y manufactura.
INBS se está preparando para ingresar al mercado de detección de drogas en EE. UU. a finales de este año, utilizando la conferencia NDASA como plataforma para interactuar con las partes interesadas de la industria y mostrar la relevancia de su solución para el mercado estadounidense.
인텔리전트 바이오 솔루션즈 (NASDAQ: INBS)는 2025년 국가 약물 및 알코올 스크리닝 협회(NDASA) 컨퍼런스에서 금 sponsor로 참여한다고 발표했습니다. 이 컨퍼런스는 플로리다주 잭슨빌에서 4월 1일부터 4일까지 열립니다. 다니엘 브라운 임상 업무 책임자가 4월 1일에 회사의 인텔리전트 핑거프린팅 약물 검사 솔루션을 발표할 예정입니다.
이 기술은 지문 땀을 이용한 휴대용 비침습적 약물 검사 방법을 제공하여 전통적인 검사 방법에 대한 대안을 제공합니다. 회사는 현재 19개국에 걸쳐 400개 이상의 계정을 보유하고 있으며, 건설, 운송, 광업 및 제조업 등 다양한 분야에서 활동하고 있습니다.
INBS는 올해 말에 미국 약물 검사 시장에 진입할 준비를 하고 있으며, NDASA 컨퍼런스를 산업 이해관계자와 소통하고 미국 시장에 대한 솔루션의 관련성을 보여주는 플랫폼으로 활용할 예정입니다.
Intelligent Bio Solutions (NASDAQ: INBS) a annoncé son sponsoring en or à la Conférence Nationale de l'Association de Dépistage des Drogues et de l'Alcool (NDASA) 2025, prévue du 1er au 4 avril à Jacksonville, en Floride. Daniel Brown, Responsable des Affaires Cliniques, présentera la Solution de Test de Drogues Intelligent Fingerprinting le 1er avril.
La technologie offre une méthode de dépistage des drogues portable et non invasive utilisant la sueur des empreintes digitales, offrant une alternative aux approches de test traditionnelles. L'entreprise sert actuellement plus de 400 clients dans 19 pays dans des secteurs tels que la construction, le transport, l'exploitation minière et la fabrication.
INBS se prépare à entrer sur le marché du dépistage des drogues aux États-Unis plus tard cette année, utilisant la conférence NDASA comme plateforme pour interagir avec les parties prenantes de l'industrie et montrer la pertinence de leur solution pour le marché américain.
Intelligent Bio Solutions (NASDAQ: INBS) hat seine Goldsponsoring für die 2025 National Drug and Alcohol Screening Association (NDASA) Konferenz angekündigt, die vom 1. bis 4. April in Jacksonville, Florida, stattfinden wird. Daniel Brown, Leiter der klinischen Angelegenheiten, wird am 1. April die Intelligent Fingerprinting Drug Testing Lösung des Unternehmens präsentieren.
Die Technologie bietet eine tragbare, nicht-invasive Methode zum Drogenscreening, die Schweiß von Fingerabdrücken nutzt und eine Alternative zu traditionellen Testansätzen darstellt. Das Unternehmen bedient derzeit über 400 Kunden in 19 Ländern in Sektoren wie Bau, Transport, Bergbau und Fertigung.
INBS bereitet sich darauf vor, später in diesem Jahr in den US-Drogenscreening-Markt einzutreten und nutzt die NDASA-Konferenz als Plattform, um mit Branchenvertretern in Kontakt zu treten und die Relevanz ihrer Lösung für den US-Markt zu präsentieren.
- Expanding into the multi-billion dollar U.S. drug screening market
- Established presence with 400+ accounts across 19 countries
- Gold sponsor status at major industry conference demonstrates market positioning
- None.
NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its participation as a gold sponsor at the 2025 National Drug and Alcohol Screening Association (NDASA) Conference and Trade Show, taking place from April 1 – 4 in Jacksonville, Florida.
Daniel Brown, Head of Clinical Affairs at Intelligent Bio Solutions, will present at the International Symposium on Tuesday, April 1, at 1:00 PM. Daniel will introduce the Company’s Intelligent Fingerprinting Drug Testing Solution, a portable, non-invasive solution designed to enable fast, on-site drug screening using fingerprint sweat. The solution is designed to provide a dignified, efficient alternative to traditional drug testing methods and to support compliance in safety-critical industries.
NDASA’s annual conference is a premier event for professionals involved in drug and alcohol testing, workplace safety, and substance abuse prevention. Attendees include HR leaders, safety professionals, treatment providers, third-party administrators, collectors, legal professionals, and government representatives.
“The NDASA conference brings together key voices in workplace drug testing,” said Daniel Brown, Head of Clinical Affairs at Intelligent Bio Solutions. “We’re proud to support its mission and contribute to the conversation around practical, respectful testing alternatives that address today’s workplace safety challenges.”
The Company’s presence at the NDASA 2025 Conference and Trade Show highlights its continued commitment to workplace safety and innovation in drug screening. With more than 400 accounts across 19 countries, INBS is expanding its reach across sectors such as construction, transportation, mining, and manufacturing. As the Company prepares to enter the multi-billion dollar U.S. drug screening market later this year, participation also provides a timely platform to engage with industry stakeholders and demonstrate the relevance of its solution to the needs of the U.S. drug screening landscape.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
For more information, visit: http://www.ibs.inc
Forward-Looking Statements:
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions' public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact:
Intelligent Bio Solutions Inc.
info@ibs.inc
LinkedIn | Twitter
Investor & Media Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
FAQ
When will Intelligent Bio Solutions (INBS) enter the U.S. drug screening market?
What is INBS's current global market presence?
What technology will INBS showcase at the 2025 NDASA Conference?
When and where is INBS presenting at the 2025 NDASA Conference?
